furazolidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1257 | 67-45-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 20, 1958 | FDA | SHIRE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G01AX06 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Other antiinfectives and antiseptics |
| ATC | P01AB51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES Nitroimidazole derivatives |
| CHEBI has role | CHEBI:35441 | antiinfective agents |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
| CHEBI has role | CHEBI:38623 | monoamine oxidase inhibitors |
| CHEBI has role | CHEBI:50685 | antitrichomonal agent |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000891 | Anti-Infective Agents, Local |
| MeSH PA | D000892 | Anti-Infective Agents, Urinary |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D000994 | Antitrichomonal Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Prevention of bacterial infection of superficial wounds, abrasions, lacerations, and pyogenic dermatitis | Indication |
| Horses | Prevention of bacterial infection of superficial wounds, abrasions, lacerations, and following firing (heat or electrocautery) | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Furox Aerosol Powder, Topazone Aerosol Powder | Kinetic Technologies LLC | 1 |
| Furall | Farnam Companies Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018877 | VUID |
| N0000147172 | NUI |
| D00830 | KEGG_DRUG |
| 4018877 | VANDF |
| C0016855 | UMLSCUI |
| CHEBI:5195 | CHEBI |
| FUR | PDB_CHEM_ID |
| CHEMBL1103 | ChEMBL_ID |
| DB00614 | DRUGBANK_ID |
| D005664 | MESH_DESCRIPTOR_UI |
| 5323714 | PUBCHEM_CID |
| 273 | INN_ID |
| 5J9CPU3RE0 | UNII |
| 224944 | RXNORM |
| 416 | MMSL |
| 4768 | MMSL |
| d00243 | MMSL |
| 002855 | NDDF |
| 416556006 | SNOMEDCT_US |
| 91314000 | SNOMEDCT_US |
Pharmaceutical products:
None